title: The impact of Campath 1H induction in adult liver allotransplantation.
abstract: BACKGROUND
  We report our experience with Campath 1H in adult liver allotransplantation.
  
  
  METHODS
  Between December 2001 and February 2004, 77 patients underwent liver transplantation using Campath 1H induction and low-dose maintenance tacrolimus immunosuppression. The control group consisted of 50 patients with similar baseline characteristics and the same eligibility criteria, transplanted under our standard Tacrolimus/steroids regimen. Hepatitis C patients were excluded from the study.
  
  
  RESULTS
  Patient and graft survival were similar for both groups. The incidence of rejection was significantly lower in the Campath vs the control group (51% vs 65% at 12 months, P = .009). Tacrolimus trough levels and conversion from Tacrolimus or the addition of other immunosuppressive drugs due to nephrotoxicity were also significantly lower in the Campath 1H group.
  
  
  CONCLUSIONS
  Campath 1H induction with low-dose Tacrolimus maintenance immunosuppression is an effective regimen in reducing acute rejection in adult liver transplantation, while maintaining lower tacrolimus levels and less nephrotoxicity than our conventional immunosuppressive regimen.
authors.affiliation: Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, Florida 33136, USA.
authors.forename: P
authors.initials: P
authors.lastname: Tryphonopoulos
authors.forename: J R
authors.initials: JR
authors.lastname: Madariaga
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Nishida
authors.forename: D M
authors.initials: DM
authors.lastname: Levi
authors.forename: J
authors.initials: J
authors.lastname: Moon
authors.forename: G
authors.initials: G
authors.lastname: Selvaggi
authors.forename: W
authors.initials: W
authors.lastname: De Faria
authors.forename: A
authors.initials: A
authors.lastname: Regev
authors.forename: P
authors.initials: P
authors.lastname: Bejarano
authors.forename: A
authors.initials: A
authors.lastname: Khaled
authors.forename: K
authors.initials: K
authors.lastname: Safdar
authors.forename: V
authors.initials: V
authors.lastname: Esquenazi
authors.forename: D
authors.initials: D
authors.lastname: Weppler
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: P
authors.initials: P
authors.lastname: Ruiz
authors.forename: J
authors.initials: J
authors.lastname: Miller
authors.forename: A G
authors.initials: AG
authors.lastname: Tzakis
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D012189:Retrospective Studies; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D016559:Tacrolimus